Drugs, genes and methemoglobinemia

Until quite recently. pharmacogenetic polymorphisms in oxidative drug metabolism were considered rare. However during the last years several monogenically determined poly of oxidative reactions in drug metabolism involving benzylic hydroxylation of debrisoquine, N-oxidation qf sparteine, C-hydroxylation qf tolbutamide, O-de-ethylation of phenacetin, phydroxylation qf phenytoin and mephenytoin and N-glucosidation of amylobarbitone (amobarbital) have been discovered. The incidence qf these various pharmacogenetic conditions varies between 2 and 9 % of the population. Among these conditions the best studied examples are the polymorphic oxidation qf debrisoquine and sparteine.

show abstract

Defective Oxidation of Drugs

Eichelbaum¹

1982

Clinical Pharmacokinetics

168

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Drugs, genes and methemoglobinemia

Cited by 1 publication

References 5 publications

Defective Oxidation of Drugs

Defective Oxidation of Drugs

Contact Info

Product

Resources

About